SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Willke R, Burke B, Erickson P. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004; 25: 53552.
  • 2
    Fairclough DL. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 2004; 13: 11538.
  • 3
    Beaton DE, Bombardier C, Katz JN, Wright JG. A taxonomy for responsiveness. J Clin Epidemiol 2001; 54: 120417.
  • 4
    Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 817.
  • 5
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 40715.
  • 6
    Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient-reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005; 64: 2933.
  • 7
    Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient-reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis 2005; 64: 347.
  • 8
    Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 103949.
  • 9
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.
  • 10
    Dougados M, le Henanff A, Logeart I, Ravaud P. Short-term symptomatic efficacy of NSAID/Coxib in rotator cuff syndrome: a 7-day placebo, diclofenac controlled study evaluating Rofecoxib. Submitted for publication.
  • 11
    Neer CS II, Watson KC, Stanton FJ. Recent experience in total shoulder replacement. J Bone Joint Surg Am 1982; 64: 31937.
  • 12
    Wells G, Anderson J, Beaton D, Bellamy N, Boers M, Bombardier C, et al. Minimal clinically important difference module: summary, recommendations, and research agenda. J Rheumatol 2001; 28: 4524.
  • 13
    Wells G, Boers M, Shea B, Anderson J, Felson D, Johnson K, et al. MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. J Rheumatol 2003; 30: 11101.
  • 14
    Sprangers MA, de Regt EB, Andries F, van Agt HB, Bijl RV, de Boer JB, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol 2000; 53: 895907.
  • 15
    Barber BL, Santanello NC, Epstein RS. Impact of the global on patient perceivable change in an asthma specific QOL questionnaire. Qual Life Res 1996; 5: 11722.